Share This Article:

Gestational carriers: A viable alternative for women with medical contraindications to pregnancy

Abstract Full-Text HTML Download Download as PDF (Size:102KB) PP. 24-31
DOI: 10.4236/ojog.2013.35A2005    3,365 Downloads   4,893 Views   Citations

ABSTRACT

Objective: Compare the efficacy of surrogate or gestational carrier (GC) cycles to that of autologous in vitro fertilization (IVF)/intracytoplasmic sperm injections (ICSI) in patients with gynecologic or medical co-morbidities contraindicative to pregnancy. Design: Retrospective cohort study. Setting: Infertility patients from a single university hospital-based program from 1998-2009. Intervention(s): 128 GC cycles from 80 intended parents were identified and compared with 15,311 IVF or ICSI cycles. Main Outcome Measure(s): The peak estradiol (E2), number of oocytes retrieved, cycle cancellation, ongoing pregnancy, and live-birth were compared between GCs and autologous IVF carriers. Indications for GC use were also identified. Multiple cycles contributed by the same patient were accounted for using multivariable generalized estimating equations and two-sided Wald p-values. Results: Uterine factors (67%) was the most common indication for using a GC, followed by non-gynecologic medical conditions including coagulopathies (13%), end stage renal disease (10%), cardiovascular disease (5%) and cancer (5%). Adjusting for age, ovulation induction in GC cycles had similar peak E2 levels and number of oocytes retrieved relative to IVF cycles (p = 0.23 and 0.43, respectively). Clinical pregnancy (49% vs. 42%, p = 0.28) and live-birth rates (31% vs. 32%, p = 0.74) were also comparable. A sub-analysis of GC cycles in those women with uterine factor indications, demonstrated significantly higher clinical pregnancy rates (OR = 2.0; CI = 1.2 - 3.5) with 60% greater odds of live-birth relative to IVF/ICSI cycles, however this odds was not statistically significant for differences in live-birth (CI = 0.9 - 2.9). Conclusions: GCs are a viable alternative to start families for patients with medical co-morbidities precluding pregnancy.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Anchan, R. , Missmer, S. , Correia, K. and Ginsburg, E. (2013) Gestational carriers: A viable alternative for women with medical contraindications to pregnancy. Open Journal of Obstetrics and Gynecology, 3, 24-31. doi: 10.4236/ojog.2013.35A2005.

References

[1] Anchan, R.M. and Ginsburg, E.S. (2012) Gestational carrier pregnancy. In: Basow, D.S., Ed., UpToDate, Waltham, 2012
[2] Steigrad, S., Hacker, N.F. and Kolb, B. (2005) In vitro fertilization surrogate pregnancy in a patient who underwent radical hysterectomy followed by ovarian transposition, lower abdominal wall radiotherapy, and chemotherapy. Fertility and Sterilit, 83, 1547. doi:10.1016/j.fertnstert.2005.01.093
[3] Meniru, G.I. and Craft, I. (1997) Assisted conception options for patients with good-prognosis cervical cancer. Lancet, 349, 542. doi:10.1016/S0140-6736(97)80093-1
[4] Siddle, N., Sarrel, P. and Whitehead, M. (1987) The effect of hysterectomy on the age at ovarian failure: Identification of a subgroup of women with premature loss of ovarian function and literature review. Fertility and Sterilit, 47, 94.
[5] Esfandiari, N., Claessens, E.A., O’Brien, A., et al. (2004) Gestational carrier is an optimal method for pregnancy in patients with vaginal agenesis (Rokitansky syndrome). International Journal of Fertility and Women’s Medicine, 49, 79.
[6] Beski, S., Gorgy, A., Venkat, G., et al. (2000) Gestational surrogacy: A feasible option for patients with Rokitansky syndrome. Human Reproduct, 15, 2326-2328. doi:10.1093/humrep/15.11.2326
[7] Brinsden, P.R. (2003) Gestational surrogacy. Human Reproduct, 9, 483-491. doi:10.1093/hum upd/dmg033
[8] Stafford-Bell, M.A. and Copeland, C.M. (2001) Surrogacy in Australia: Implantation rates have implications for embryo quality and uterine receptivity. Reproduction, Fertility and Development, 13, 99-104. doi:10.1071/RD00044
[9] Marrs, R.P., Ringler, G.E., Stein, A.L., et al. (1993) The use of surrogate gestational carriers for assisted reproductive technologies. American Journal of Obstetrics & Gynecology, 168, 1858-1863. doi:10.1016/0002-9378(93)90702-K
[10] Farley, D.M., Grainger, D.A., Tjaden, B.L., et al. (2007) Use of a gestational carrier for a patient with recurrent adverse pregnancy outcomes from early onset severe preeclampsia. Fertility and Sterilit, 87, 189.
[11] Pellicer, A., Simón, C. and Remohí, J. (1995) Effects of aging on the female reproductive system. Human Reproduct, 10, 77-83. doi:10.1093/humrep/10.suppl_2.77
[12] Cano, F., Simón, C., Remohí, J. and Pellicer, A. (1995) Effect of aging on the female reproductive system: Evidence for a role of uterine senescence in the decline in female fecundity. Fertility and Sterilit, 64, 584.
[13] Utian, W.H., Goldfarb, J.M., Kiwi, R., et al. (1989) Preliminary experience with in vitro fertilization-surrogate gestational pregnancy. Fertility and Sterilit, 52, 633.
[14] Meniru, G.I. and Craft, I.L. (1997) Experience with gestational surrogacy as a treatment for sterility resulting from hysterectomy. Human Reproduct, 12, 51-54. doi:10.1093/humrep/12.1.51
[15] Utian, W.H., Sheean, L., Goldfarb, J.M. and Kiwi, R. (1985) Successful pregnancy after in vitro fertilization and embryo transfer from an infertile woman to a surrogate. The New England Journal of Medicine, 313, 1351-1352. doi:10.1056/NEJM198511213132112
[16] Marino, F. (2010) Global issues: Adoption and surrogate pregnancy. Infobase Publishing, New York.
[17] www.cdc.gov
[18] Braverman, A.M. and Corson, S.L. (1992) Characteristics of participants in a gestational carrier program. Journal of Assisted Reproduction and Genetics, 9, 353-357. doi:10.1007/BF01203959
[19] Pirhonen, J., Bergersen, T.K., Abdlenoor, M., et al. (2005) Effect of maternal age on uterine flow impedance. Journal of Clinical Ultrasound, 33, 14-17. doi:10.1002/jcu.20079
[20] Brinsden, P.R., Appleton, T.C., Murray, E., et al. (2000) Treatment by in vitro fertilisation with surrogacy: Experience of one British centre. BMJ, 320, 924. doi:10.1136/bmj.320.7239.924
[21] Batzofin, J., Nelson, J., Wilcox, J., et al. (1999) Gestational surrogacy: Is it time to include it as part of ART? ASRM Annual Meeting Programme Supplement.
[22] Goldfarb, J.M., Austin, C., Peskin, B., et al. (2000) Fifteen years experience with an in-vitro fertilization surrogate gestational pregnancy programme. Human Reproduct, 15, 1075-1078. doi:10.1093/humrep/15.5.1075
[23] Raziel, A., Schachter, M., Strassburger, D., et al. (2005) Eight years’ experience with an IVF surrogate gestational pregnancy programme. Reproductive BioMedicine Online, 11, 254-258. doi:10.1016/S1472-6483(10)60966-2
[24] Corson, S.L., Kelly, M., Braverman, A.M. and English, M.E. (1998) Gestational carrier pregnancy. Fertility and Sterilit, 69, 670-674. doi:10.1016/S0015-0282(98)00020-X
[25] Gibbons, W.E., Cedars, M. and Ness, R.B. and Society for Assisted Reproductive Technologies Writing Group (2011) Toward understanding obstetrical outcome in advanced assisted reproduction: Varying sperm, oocyte, and uterine source and diagnosis. Fertility and Sterilit, 95, 1645-1649. doi:10.1016/j.fertnstert.2010.11.029
[26] Ubaldi, F., Rienzi, L., Baroni, E., et al. (2003) Implantation in patients over 40 and raising FSH levels—A review. Placenta, 24, S34-S38. doi:10.1016/S0143-4004(03)00179-6
[27] Abdalla, H.I., Wren, M.E., Thomas, A. and Korea, L. (1997) Age of the uterus does not affect pregnancy or implantation rates; A study of egg donation in women of different ages sharing oocytes from the same donor. Human Reproduct, 12, 827-829. doi:10.1093/humrep/12.4.827
[28] Navot, D., Drews, M.R., Bergh, P.A., et al. (1994) Agerelated decline in female fertility is not due to diminished capacity of the uterus to sustain embryo implantation. Fertility and Sterilit, 61, 97.
[29] Brinsden, P.R. (1999) Surrogacy. In: Brinsden, P.R., Ed., A textbook of in vitro fertilization and assisted reproduction, Parthenon, Carnforth and New York.
[30] Cherry, A.L. (2011) Nurturing in the service of white culture: Racial subordination, gestational surrogacy, and the ideology of motherhood. Texas Journal of Women and the Law, 10, 83.
[31] Pretorius, D. (1994) Surrogate motherhood: A worldwide view of the issues. The New England Journal of Medicine, 331, 685.
[32] Golombok, S., MacCallum, F., Murray, C., et al. (2006) Surrogacy families: Parental functioning, parent-child relationships and children’s psychological development at age 2. Journal of Child Psychology and Psychiatry, 47, 213-222. doi:10.1111/j.1469-7610.2005.01453.x
[33] Van Zyl, L. (2002) Intentional parenthood: Responsibilities in surrogate motherhood. Health Care Analysis, 10, 165-175. doi:10.1023/A:1016550002211
[34] Fuscaldo, G. (2006) Genetic ties: Are they morally binding? Bioethics, 20, 64-76. doi:10.1111/j.1467-8519.2006.00478.x
[35] Bravennan, A.M. and Corson, S.L. (2002) A comparison of oocyte donors’ and gestational carriers/surrogates’ attitudes towards third party reproduction. Journal of Assisted Reproduction and Genetics, 19, 462-469. doi:10.1023/A:1020306402235
[36] Gunn, W. (1994) Bioethics and law: Standard of care: The law of American bioethics. JAMA, 271, 795. doi:10.1001/jama.1994.03510340085047
[37] Yamamoto, K. and Moore, S.A. (2011) A trust analysis of a gestational carrier’s right to abortion. Fordham Law Review, 70, 93.
[38] Rosen, A. (2005) Third-party reproduction and adoption in cancer patients. JNCI Monographs, 2005, 91-93. doi:10.1093/jncimonographs/lgi021
[39] MacCallum, F., Lycett, E., Murray, C., et al. Surrogacy: The experience of commissioning couples. Human Reproduct, 18, 1334-1342. doi:10.1093/humrep/deg253
[40] Massachusetts’ Supreme Judicial Court (2001) Culliton v. Beth Israel Deaconess Medical Center. Wests North East Rep., 756, 1133-1141.
[41] Committee on Ethics (2008) ACOG committee opinion number 397, February 2008: Surrogate motherhood. Obstetrics & Gynecology, 111, 465.
[42] Guichon, J. (2007) The body, emotions and intentions: Challenges of preconception arrangements for health care providers. CMAJ, 176, 479-481. doi:10.1503/cmaj.061595
[43] Reilly, D.R. (2007) Surrogate pregnancy: A guide for Canadian prenatal health care providers. CMAJ, 176, 483-485. doi:10.1503/cmaj.060696
[44] Adams, K.E. (2003) Gestational surrogacy for a human immunodeficiency virus seropositive sperm donor: What are the ethics? Journal of the American Medical Women’s Association, 58, 138.
[45] Duffy, D.A., Nulsen, J.C., Maier, D.B., et al. (2005) Obstetrical complications in gestational carrier pregnancies. Fertility and Sterilit, 83, 749-754. doi:10.1016/j.fertnstert.2004.08.023
[46] Parkinson, J., Tran, C., Tan, T., et al. (1999) Perinatal outcome after in-vitro fertilization-surrogacy. Human Reproduct, 14, 671-676. doi:10.1093/humrep/14.3.671

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.